

# Autoimmune Disease Therapeutics: Market Research Report

<https://marketpublishers.com/r/AC883E0E9A9EN.html>

Date: October 2011

Pages: 749

Price: US\$ 4,500.00 (Single User License)

ID: AC883E0E9A9EN

## Abstracts

This report analyzes the worldwide markets for Autoimmune Disease Therapeutics in US\$ Million by the following Therapeutic Class: Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics), and Others.

The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

Also, a six-year historic analysis is provided for these markets.

The report profiles 112 companies including many key and niche players such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Elan Corporation, plc, Eli Lilly And Company, F.Hoffmann-la Roche AG, Chugai Pharmaceutical Co., Ltd., Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck & Co., Inc, Merck Serono SA, Novartis AG, Sanofi-aventis SA , Shire Plc, Teva Pharmaceuticals Industries Limited, and UCB S.A.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

## Contents

### **1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS**

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definition and Scope of Study

Rheumatoid Arthritis

Multiple Sclerosis

Psoriasis

Crohn's disease

### **2. INDUSTRY OVERVIEW & OUTLOOK**

Autoimmune Disease Therapeutics Market Continues to Flourish

Pharmaceutical Industry Hit by Economic Downturn

Economic Downturn Takes Toll on R&D

Current and Future Analysis

Segment Analysis

Rheumatoid Arthritis Therapeutics – The Largest Segment

Multiple Sclerosis Therapeutics Market

Crohn's Disease Therapeutics Market

Ulcerative Colitis Drugs Market

### **3. MARKET DYNAMICS AND TRENDS**

Biologics Find Acceptance as First Line of Treatment for Autoimmune Diseases

High Unmet Need Favors Growth

Impact of Biosimilars Legislation on Biologic Arthritis Drugs Market

New Products to Drive Market Growth

Biogenerics to Expand Adoption of Biological Drugs

Risk of Cancer Due to Anti-TNF Drugs

Superior Outcomes to Enhance Adoption of Biologics

Efficacy and Convenience – Key Factors Driving Physician's Decision

### **4. DISEASE OVERVIEW**

Immunity and Immune System  
Autoimmune Diseases  
Women- Highly Susceptible to Autoimmune Diseases

**Table 1.** Percentage Breakdown of Incidence of Autoimmune Diseases in Men and Women (includes corresponding Graph/Chart)

Complexity in Manifestations Renders Difficulty in Understanding the Conditions  
Etiology of Autoimmune Diseases  
Genetic Predisposition  
Environmental Factors  
Autoimmune Diseases – A Social and Health Burden  
Regulatory Glitches and High Costs Hinder Biogenerics  
Types of Autoimmune Diseases  
Incidence and Prevalence  
Diagnosis and Treatment of Autoimmune Diseases  
Overview on Select Biologic Drugs  
Remicade  
Humira  
Rituxan® (rituximab)  
Cimzia  
Cimzia to Face Stiff Competition in Rheumatoid Arthritis Market  
Psoriasis – A Promising Market for Cimzia  
Actemra  
Enbrel

## **5. OVERVIEW OF SELECT AUTOIMMUNE DISEASES**

Rheumatoid Arthritis  
Disease Overview  
Low Penetration to Sustain growth of Anti-TNF Drugs  
Incidence and Prevalence Higher in Urban and Developed Regions  
Symptoms and Diagnosis  
Treatment of Rheumatoid Arthritis  
BRMs Revolutionize RA Treatment  
Branded Products  
Drugs Used in Treating Rheumatoid Arthritis  
Year of Approval of Leading Biologics in Rheumatoid Arthritis Therapy

## Key Drugs in Late Stage Development for Rheumatoid Arthritis Treatment Competitive landscape

### **Table 2.** Comparative Analysis of Leading Biologic Rheumatoid Arthritis Drugs based on ACR Scores by End Point

High Prices and Safety Concerns

Multiple Sclerosis

Etiology

Types of Multiple Sclerosis

### **Table 3.** Prevalence of Different Types of Multiple Sclerosis

Pathology

Prevalence of Multiple Sclerosis High in Women

Facts About Multiple Sclerosis

Treatment

Interferon Drugs - High Efficacy Drugs in Existing MS Therapies

Beta Interferon Drugs in Multiple Sclerosis Treatment

Non-Interferon Drugs

Non-Interferon Drugs in Multiple Sclerosis Treatment

Trends in Multiple Sclerosis Market

High Unmet Need and Rich Pipeline to Expand MS Market

Interferon-based Drugs Lead Multiple Sclerosis Drug Market

Oral Drugs Alter Dynamics in MS Therapies Market

Dip in Sales Inevitable for Current Therapies

Tough Times Ahead for Betaseron

Competitive landscape

### **Table 4.** Leading Products/Companies in the Global Multiple Sclerosis Therapeutics Market (2010): Percentage Share Breakdown of Value Sales for Biogen Idec, Teva/sanofi-aventis\*, Merck Serono, Bayer Schering, Elan, and Others (includes corresponding Graph/Chart)

Multiple Sclerosis Drug Pipeline – An Overview

Drugs Under Development for Treating Multiple Sclerosis

Fingolimod (Gilenya)  
Mylinax  
Laquinimod  
Campath (Alemtuzumab)  
Teriflunomide  
Fampridine-SR  
BG-12 (Oral Fumarate)  
MN-166  
Psoriasis  
Prevalence  
Available Treatment Options  
Biological Drugs  
Biological Drugs Lead the Fray  
Potential Therapeutic Products  
Inflammatory Bowel Diseases  
Crohn's disease  
Stages of the Disease  
Prevalence  
Diagnosis  
Treatment  
Ulcerative Colitis  
Diagnosis and Treatment  
Other Diseases  
Systemic Lupus Erythematosus (SLE)  
Prevalence and Epidemiology  
Treatment  
Sjogren's Syndrome  
Prevalence and Epidemiology  
Diagnosis and Treatment  
Type-1 Diabetes Mellitus  
Types of Diabetes Mellitus  
Type 1 or Insulin Dependent Diabetes Mellitus  
Type 2 or Non-Insulin Dependent Diabetes Mellitus  
Insulin – Vital for Blood Glucose Management  
Etiology  
Prevalence  
Diabetes in Children - A Growing Concern  
Diagnosis and Treatment  
Autoimmune Hepatitis

Disease Categories  
Treatment  
Side Effects  
Juvenile Rheumatoid Arthritis  
Symptoms  
Diagnosis  
Scleroderma  
Prevalence  
Etiology  
Diagnosis  
Management  
Vasculitis Syndromes  
Haematologic Autoimmune Diseases  
Ankylosing Spondylitis

## **6. CLINICAL TRIALS & RESEARCH STUDIES**

Antares Pharma Commences VIBEX MTX Clinical Trial for Treating Rheumatoid Arthritis  
Avila Therapeutics Introduces Btk Inhibitor for Treating Autoimmune Diseases and Cancer  
Athersys and Angiotech to Conduct MultiStem® Clinical Trial  
BioMarin Commences Amifampridine Phosphate Clinical Trial for Treating LEMS  
TxCell Successfully Completes Trial for Crohn's Disease Cell Therapy  
Novartis Releases Phase II Data for AIN457  
Sanofi Releases Phase III TEMSO Study Results of Teriflunomide  
Biogen Achieves Positive Results for BG-12 Drug Trial  
Innate Therapeutics Commences MIS416 Clinical Trial in Progressive MS Patients  
Pfizer Completes Clinical Trials for Tasocitinib  
Compugen Completes Animal Model Study of CGEN-15001  
Avila Therapeutics Commences AVL-292 Clinical Trial  
Horizon Pharma Completes Clinical Trials for LODOTRA®  
ChemoCentryx Begins Phase 1 Clinical trial for CCX168  
NYU Langone Medical Center Announces Potential Therapy for Rheumatoid Arthritis  
Compugen to Start Preclinical Development for Therapeutic Drugs  
Avila Therapeutics Begins Phase I Clinical Trial for AVL-292  
VBL Therapeutics Releases Preclinical Data for VB-201  
GlaxoSmithKline and Dynavax Select DV1179 for Endosomal TLR Inhibitor Program  
Idera Pharmaceuticals Starts Phase 1 Clinical Study of IMO-3100

ChemoCentryx Begins Phase I Clinical Study of CCX168  
VBL Therapeutics Starts Phase II Clinical Study of VB-201  
ChemoCentryx Begins Phase II Clinical Study of CCX354  
Neovacs Starts Phase IIa Clinical Study of TNF Kinoid  
Galapagos Begins Phase II Clinical Study of Nanocort  
Plexxikon Starts Dosing of PLX3397 in Phase I Clinical Study

## **7. PRODUCT INTRODUCTIONS/APPROVALS**

Horizon Pharma Receives FDA Approval for DUEXIS®  
Venus Remedies to Launch Trois  
CNRS/Inserm Researchers Introduce Dendrimer ABP as RA Therapy  
Food and Drug Monitoring Agency to Approve Tocilizumab for Commercial Use  
Novartis Bags EC Approval for Gilenya®  
Genentech Obtains FDA Approval for ACTEMRA  
Novartis Gains Approval for Gilenya in Japan  
Novartis Receives FDA Approval for Gilenya  
Compugen Discovers and Validates CGEN-15001 Soluble Recombinant Fusion Protein  
InNexus Biotechnology Develops IXSCD11a  
Centocor Ortho Biotech Submits sBLA for Simponi Label Extension  
Osiris Therapeutics Obtains Orphan Drug Designation for Prochymal from FDA  
Immunomedics Obtains US Patent for Immunotherapy  
Biogen Idec Introduces Monoclonal Antibody Tysabri in India  
Merck Serono Unveils Pre-Filled Pen RebiDose™ in UK  
BioMarin Unveils Firdapse™ in European Union  
Sandoz Introduces Calcipotriene Solution in US  
Cimzia® Receives FDA Approval for Treating Rheumatoid Arthritis  
Simponi™ Receives FDA Approval for Treating Rheumatoid Arthritis  
Novartis Introduces Extavia® for Multiple Sclerosis Treatment in Denmark & Germany  
Novartis Bags FDA Approval for Extavia  
UCB Receives EC Approval for Cimzia  
Centocor Ortho Biotech Receives FDA Approval for Stelara  
BioMarin Pharmaceutical Bags FDA's Orphan Drug Designation  
Promius Pharma Introduces Scytera™ for Psoriasis Treatment  
Galderma Receives FDA Approval for Plaque Psoriasis Ointment Vectical™  
Roche Obtains EC Approval for Rheumatoid Arthritis Antibody RoACTEMRA  
Viron Therapeutics Obtains US Patents for VT-384, VT-346 Candidates  
Bayer Schering Pharma Obtains Approval for Betafron® Therapy from SFDA  
US Food and Drug Administration Approves Certolizumab Pegol

Nitec Unveils Lodotra® in Germany

## **8. PRODUCT INNOVATIONS/INTRODUCTIONS IN THE RECENT PAST – A PERSPECTIVE BUILDER**

HUMIRA® Obtains EU Approval for Polyarticular Juvenile Idiopathic Arthritis  
Cimzia® Receives FDA Nod for Treating Crohn's Disease  
HUMIRA® Obtains Approval from Japanese Ministry for Rheumatoid Arthritis  
HUMIRA® Receives FDA Clearance for Polyarticular Juvenile Idiopathic Arthritis  
Abbott Receives EU Marketing Authorization for Humira in Psoriasis Treatment  
Xian-Janssen Introduces Remicade, Branded infliximab in China  
HUMIRA® Obtains EU Approval for Treating Crohn's Disease  
HUMIRA® Obtains FDA Approval for Crohn's Disease  
Remicade® Obtains Approval for Use in PsA and Early RA in Australia  
Tysabri™ Receives Health Canada Approval for Use in Multiple Sclerosis  
Rituxan® Gets FDA Approval for Use in RA  
Humira® Obtains FDA Approval for Treating AS  
Betaseron® Receives FDA Approval for Use in First Clinical Episode of MS  
Abbott Receives FDA Clearance for HUMIRA Pen  
Remicade Obtains FDA Approval for Treating Pediatric Crohn's Disease

## **9. RECENT INDUSTRY ACTIVITY**

Sanofi-Aventis Takes over Genzyme  
Daiichi Sankyo to Acquire Plexxikon  
TiGenix Takes Over Cellerix  
Alkermes and Elan Drug Technologies to Merge Operations  
Pfizer Japan Inks Agreements with Takeda to Co-Promote RA Drugs  
Viropro Inks Letter of Agreement with Spectrum Pharmaceuticals  
Pepscan Therapeutics Collaborates with Phylogica  
Lycera Enters into Research Collaboration with Merck  
Merck Amends Distribution Agreement with Johnson & Johnson  
Yale University and Debiopharm Enter into License Agreement for Debio 1036  
Opexa Therapeutics Inks Agreement with American Red Cross  
Antitope and NasVax Enter into Research Collaboration  
SuppreMol Inks In-License Agreement with Bayerische Patentallianz  
Glenmark Inks License Agreement with Sanofi  
Exagen Enters into Partnership with Medco  
Phylogica Inks Research Collaboration and Option Agreement with Pepscan



## Therapeutics

Merck Sharp & Dohme Enters into Partnership with Lycera

Amgen Enters into Collaboration with Xencor

PhRMA Announces Development of Medicines Targeted Towards Women

Circassia Secures Global Development and Marketing Rights to PAP-1 from Airmid

UCB Establishes Microbial Production Facility

Emergent BioSolutions Takes Over Trubion Pharmaceuticals

Gilead Sciences to Takeover CGI Pharmaceuticals

Abbott Laboratories Acquires Facet Biotech

Merck Takes Over Millipore

Quidel to Snap Up Diagnostic Hybrids

Nitec Pharma Merges with Horizon Therapeutics

Femta Pharmaceuticals Inks Manufacturing Agreement with Lonza Group

Horizon Pharma Signs Agreement with Mundipharma International

3SBIO SIGNS AGREEMENT WITH ISOTECHNIKA PHARMA

Fast Forward and Provid Pharmaceuticals Extend Partnership

Antitope and PIKAMAB Collaborate

Ligon Discovery Enters into Agreement with Lycera

Axxam, Fast Forward and Juvenile Diabetes Research Foundation Enter into Partnership

GlaxoSmithKline Collaborates with ChemoCentryx

Perseid Signs Agreement with Astellas Pharma for CTLA4-Ig Program

Cellceutix Chooses Destum Partners for KM-133 Psoriasis Compound

NERC Commences Operations of IXO Therapeutics

Avesthagen to Market Avent

Isotechnika Pharma Divests Stake in Isodiagnostika

MacroGenics Obtains New Grants from NIH

AnaptysBio Collaborates with VLST to Generate Novel Antibody Therapeutics

AstraZeneca Enters into Exclusive License Agreement with Rigel Pharmaceuticals

Immutep Inks License Agreement with GlaxoSmithKline for Therapeutic Antibody IMP731

Novo Nordisk Inks Research Collaboration Agreement with Combine

Xention and Axxam Enter into Autoimmune Disorder Research Partnership

Roche Takes Over Genentech

Merck Acquires Schering-Plough

Pfizer Takes Over Wyeth

Amgen Takes Over Immunex

BioMarin Pharmaceutical Takes Over Huxley Pharmaceuticals

Onyx to Takeover Proteolix

Genzyme Takes Over Global Rights of Campath, Leukine and Fludara from Bayer  
Bristol-Myers Squibb Enters into Agreement with Alder Biopharmaceuticals  
LEO Pharma Inks Agreement with Warner Chilcott  
Kineta One Acquires Commercial Rights for Compounds from Airmid  
Kineta Signs Agreement with Alturas Analytics  
Catalyst Biosciences in Research and License Agreement with MedImmune  
Boehringer Ingelheimes Collaborates with Exelixis  
Lonza Signs Agreement with Opsona Therapeutics for Manufacturing Antibody  
Eli Lilly and Incyte Enter into Agreement  
Novartis Option Fund and Avila Therapeutics Sign Option Agreement  
Genentech Acquires Rights for BHT-3021 from Bayhill Therapeutics  
Celentyx and Meiji Seika Kaisha Ink Agreement  
Exelixis and Boehringer Ingelheim Enter into Autoimmune Disease Partnership  
Celldex Acquires Exclusive Rights of Immune-Stimulatory Molecules from Amgen  
Apitope and Merck Serono Sign Agreement for Multiple Sclerosis Drug  
Biovitrum and Affibody® Enter into Collaboration  
Bayhill Therapeutics Bags Contract from Genentech

## **10. CORPORATE ACTIVITY IN THE RECENT PAST – A PERSPECTIVE BUILDER**

Novo Nordisk and VLST Collaborate on Therapeutic Targets Development  
Actemra's Approval Gets Delayed  
Apitope Raises Financing for Developing Multiple Sclerosis Compound  
CalciMedica to Acquire Rights to STIM1 from TorreyPines  
Roche Acquires ARIUS Research, Inc.  
Astellas Inks Agreement with Maxygen for MAXY-4 Candidates  
Carna and Caliper Life Sciences Ink Collaborative Supply Agreement  
Isotechnika Gets Back Worldwide Rights to Transplant Drug, Voclosporin  
Boehringer In-licenses Two Drug Targets from BioFocus  
Bionomics Enters into a Development and Licensing Agreement with Merck Serono  
Nycomed Inks Agreement with Immunomedics for Veltuzumab  
EpiVax Receives Grants from National Institutes of Health to Advance Epi-13  
Boehringer to Takeover Actimis  
Antisoma Acquires Xanthus Pharmaceuticals  
Merrimack Acquires Funds for Developing Cancer and Autoimmune Disease Biologics  
BioSeek and Merck Sign Collaboration Agreement for Compound Evaluation  
Questcor Amends Distribution Contract with US Distributor of Acthar  
ANP Completes Phase IIa Trial for Multiple Sclerosis Drug  
Insert and Calando Merge to Form Calando Pharmaceuticals

Codon Inks Research & Development and Licensing Deal with Merrimack  
Debiopharm Inks licensing Deal with Airmid for Debio 0824 ShK Peptide  
Chelsea Acquires Global Rights to I-3D Range of DHODH Inhibiting Compounds  
Cypress Bioscience Acquires Proprius  
J&J PRD Grants Milestone Payment to Sunesis Pharmaceuticals  
GlaxoSmithKline Acquires License to Market Vaccinex's Antibody  
Teva to Takeover CoGenesys  
Hadasit, HMS and BWH to Co-develop Oral Therapy for Autoimmune Diseases  
Anthera Acquires Rights to Develop and Market AMG 623 from Amgen  
Can-Fite Enters into Two Cooperation Agreements to Develop CF102 Drug  
Source MDx Inks an Agreement with Pfizer  
Cambridge Inks an Antibody Development Agreement with Medarex  
Pfizer to Acquire Coley Pharma  
GSK Joins Hands with Tolerx to Develop and Commercialize oteelixizumab  
Amgen Acquires Avidia  
Eli Lilly and MacroGenics Tie Up for Developing Teplizumab  
MorphoSys and Genesis Ink Antibody R&D Deal  
arGentis Enters into a License Agreement with UTRF  
Eden Biodesign to Investigate Novel Drug Candidate for Autoimmune Diseases  
Nuon and Kissei Team up for Tranilast  
Organon and Dyax Team Up for Developing Therapeutic Antibodies  
Medarex Joins Hands with Mitsubishi for Monoclonal Antibody Development  
Merck and Archemix Collaborate  
Genzyme Takes Over Bioenvision  
Organon and Medarex Ink Drug Development Deal  
CalciMedica Secures Exclusive Rights for CBR's Autoimmune Drug Target  
Xanthus Secures Exclusive Patent Estate Rights for FLT3 Pathway  
Eisai Corporation Acquires Morphotek  
TIRC Changes Name to Orchestra Therapeutics  
Abbott Files HUMIRA® for Psoriasis in the US and EU (USA/Europe)  
Accentia Secures Exclusive Global Rights to Revimmune  
Medarex and Compugen Ink Collaborative Agreement for Therapeutic Antibody  
SRI and Telik Sign License Agreement for Drug Development  
China Biopharma Signs Agreement with Chinese Biopharmaceutical Firm  
Kirin and Astellas Ink Licensing Agreement for Anti-CD40 Antagonistic mAb  
QSV and Artielle Sign Contract to Produce RTL-1000  
JDRF and MacroGenics Form Partnership  
GSK and Genmad Sign Partnership Agreement for HuMaxCD20  
Biocon Enters into Joint Venture Agreement with Neopharma

Pipex Pharmaceuticals Acquires Remaining Stake in Effective Pharmaceuticals  
Astellas Acquires Worldwide Rights for Amevive®  
Biogen Acquires Fumapharm  
Biogen and UCB Join Hands for Oral Multiple Sclerosis Therapy

## 11. FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories (USA)  
Amgen Inc. (USA)  
Bayer Schering Pharma AG (Germany)  
Biogen Idec Inc. (USA)  
Bristol-Myers Squibb Company (USA)  
Elan Corporation plc (Ireland)  
Eli Lilly and Company (USA)  
F. Hoffmann-La Roche AG (Switzerland)  
Chugai Pharmaceutical Co. , Ltd. (Japan)  
Genentech, Inc. (USA)  
GlaxoSmithKline Plc (UK)  
Johnson & Johnson, Inc. (USA)  
Merck & Co. , Inc. (US)  
Merck Serono SA (Switzerland)  
Novartis AG (Switzerland)  
Sanofi-aventis SA (France)  
Shire Plc (Ireland)  
Teva Pharmaceuticals Industries Limited (Israel)  
UCB S. A. (Belgium)

## 12. GLOBAL MARKET PERSPECTIVE

**Table 5.** World Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 6.** World Historic Review for Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 7.** World 15-year Perspective for Autoimmune Disease Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 8.** World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 9.** World Historic Review for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 10.** World 15-year Perspective for Rheumatoid Arthritis Therapeutics (Biologics) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 11.** World Recent Past, Current & Future Analysis for Multiple Sclerosis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 12.** World Historic Review for Multiple Sclerosis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 13.** World 15-year Perspective for Multiple Sclerosis Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 14.** World Recent Past, Current & Future Analysis for Psoriasis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 15.** World Historic Review for Psoriasis Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 16.** World 15-year Perspective for Psoriasis Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 17.** World Recent Past, Current & Future Analysis for Crohn's Disease Therapeutics (Biologicals) by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 18.** World Historic Review for Crohn's Disease Therapeutics (Biologicals) by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 19.** World 15-year Perspective for Crohn's Disease Therapeutics (Biologicals) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

**Table 20.** World Recent Past, Current & Future Analysis for Other Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World- Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 21.** World Historic Review for Other Autoimmune Disease Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 22.** World 15-year Perspective for Other Autoimmune Disease Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## 13. THE UNITED STATES

### A. MARKET ANALYSIS

Current and Future Analysis  
Autoimmune Diseases Fact Sheet

**Table 23.** Prevalence of Key Autoimmune Diseases in the US (in Millions) (includes corresponding Graph/Chart)

Market Trends

Biologic Drugs Lead the Fray

Biologics To Add Further Impetus to the Market

Rheumatoid Arthritis Drugs Lead the Market

Enbrel and Humira Continue to Gain Share in the Anti-TNF Market

Increased Incidence and Rise in Drug Prices to Drive Growth in MS Market

**Table 24.** Leading Multiple Sclerosis Drugs in the US (2008): Percentage Share Breakdown of New Prescriptions Written for Avonex, Copaxone, Rebif, Betaseron, and Tysabri (includes corresponding Graph/Chart)

Incidence of Type 1 Diabetes Mellitus Endemic in White Youth

Lialda's Share Gaining Momentum in Ulcerative Colitis Drugs Market

Key Ulcerative Colitis Drugs Market in the US (2006)

Product Launches/Approvals

Strategic Corporate Developments

Key Players

### B. MARKET ANALYTICS

**Table 25.** US Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 26.** US Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 27.** US 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## 14. JAPAN

### A. MARKET ANALYSIS

Current and Future Analysis

Japanese Patients Exhibit Unique Efficacy & Safety Effects

Product Launches/Approvals

Strategic Corporate Developments

Key Players

### B. MARKET ANALYTICS

**Table 28.** Japanese Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 29.** Japanese Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 30.** Japanese 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other



Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## 15. EUROPE

### A. MARKET ANALYSIS

Current and Future Analysis

Europe – A Burgeoning Market for Autoimmune Disease Therapeutics

Increasing Awareness to Drive Market Growth

Low Penetration to Fuel Growth in European MS DMDs Market

**Table 31.** Prevalence of Key Autoimmune Diseases in Europe in Millions (includes corresponding Graph/Chart)

Lower Treatment Rate Bodes Huge Potential for the UK MS Drug Market

Drugs Hindering Disease Progression to Gain Prominence

Rising Demand for Rheumatoid Arthritis Drugs in Russia

Product Launches/Approvals

Strategic Corporate Developments

Key Players

### B. MARKET ANALYTICS

**Table 32.** European Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 33.** European Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 34.** European 15-Year Perspective for Autoimmune Disease Therapeutics by

Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics), and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

## **16. REST OF WORLD**

### **A. MARKET ANALYSIS**

Current and Future Analysis

Canada

Canada – Highest Prevalence Rates for Multiple Sclerosis

Sales of Biologics on the Rise in Canadian Rheumatoid Arthritis Drugs Market

Asia-Pacific

Autoimmune Diseases Market in Asia-Pacific – An Overview

Incidence of Multiple Sclerosis in India on the Rise

Overview of Rheumatoid Arthritis in Australia

**Table 35.** Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Age Group (includes corresponding Graph/Chart)

**Table 36.** Percentage Breakdown of Prevalence of Rheumatoid Arthritis in Australia by Sex (includes corresponding Graph/Chart)

Overview of Irritable Bowel Diseases in Australia

Product Launches/Approvals

Strategic Corporate Developments

Key Player

### **B. MARKET ANALYTICS**

**Table 37.** Rest of World Recent Past, Current & Future Analysis for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 38.** Rest of world Historic Review for Autoimmune Disease Therapeutics by Disease Segment – Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 39.** Rest of World 15-Year Perspective for Autoimmune Disease Therapeutics by Disease Segment – Percentage Breakdown of Dollar Sales for Rheumatoid Arthritis (Biologics), Multiple Sclerosis, Psoriasis, Crohn’s Disease (Biologics) and Other Autoimmune Diseases for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Total Companies Profiled: 112 (including Divisions/Subsidiaries - 124)

Region/Country/Players

The United States 77

Canada

Japan

Europe

France

Germany

The United Kingdom

Rest of Europe

Asia-Pacific (Excluding Japan)

Middle East

## I would like to order

Product name: Autoimmune Disease Therapeutics: Market Research Report

Product link: <https://marketpublishers.com/r/AC883E0E9A9EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AC883E0E9A9EN.html>